Amorfix and QED Bioscience announce agreement to develop novel monoclonal antibodies for cancer
28-Jun-2010 -
Amorfix Life Sciences and QED Bioscience announced that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes (DSE's) on ...
AIDS
monoclonal antibodies
multiple myeloma